Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calliditas Therapeutics (CALT)
NASDAQ:CALT
RESEARCH TOOLSreports
Calliditas Therapeutics (CALT) Stock Price & Analysis
120 Followers
CALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.25 - $41.90
Previous Close$38.72
Volume2.33K
Average Volume (3M)14.21K
Market Cap
$1.04B
Enterprise Value$951.88M
Total Cash (Recent Filing)kr973.73M
Total Debt (Recent Filing)kr27.09M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 13, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding26,836,035
10 Day Avg. Volume16,493
30 Day Avg. Volume14,206
Standard Deviation0.23
R-Squared0.16
Alpha0.00891
Financial Highlights & Ratios
Price to Book (P/B)-7.19
Price to Sales (P/S)1.29
Price to Cash Flow (P/CF)11.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.17Price Target Upside-9.17% Downside
Rating ConsensusHold
Number of Analyst Covering6
Calliditas Therapeutics News
PremiumCompany Announcements
Calliditas Therapeutics’ Annual Meeting Highlights
PremiumCompany Announcements
CHMP Endorses Calliditas’ Kinpeygo for IgANBulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition price more than adequately reflects the value of Tarpeyo and Calliditas’ pipeline.
Patent PortfolioCALT's patent portfolio was recently strengthened with MOU patent listed in Orange Book with 2043 expiry.
Product ApprovalTarpeyo's full approval with a broad label has potential to accelerate uptake.
Bears Say
Data ReliabilityIt is unclear exactly how the PFS and OS curves were constructed, raising questions around the reliability of the cited HRs.
Financial PerformanceThe rating on CALT is downgraded to Neutral from Buy, with a new price target of $39.
Operational IssuesQ1 revenues were impacted by a cyber-attack on Change Health, Calliditas’ exclusive specialty pharmacy’s insurance claims processor.
---
Ownership Overview
0.00%
Insiders
0.02% Mutual Funds
2.64% Other Institutional Investors
97.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CALT FAQ
What was Calliditas Therapeutics’s price range in the past 12 months?
Calliditas Therapeutics lowest stock price was $15.25 and its highest was $41.90 in the past 12 months.
What is Calliditas Therapeutics’s market cap?
Currently, no data Available
When is Calliditas Therapeutics’s upcoming earnings report date?
Calliditas Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is in 28 days.
How were Calliditas Therapeutics’s earnings last quarter?
Calliditas Therapeutics released its earnings results on May 23, 2024. The company reported -$0.856 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.665.
Is Calliditas Therapeutics overvalued?
According to Wall Street analysts Calliditas Therapeutics’s price is currently Overvalued.
Does Calliditas Therapeutics pay dividends?
Calliditas Therapeutics does not currently pay dividends.
What is Calliditas Therapeutics’s EPS estimate?
Calliditas Therapeutics’s EPS estimate is -$0.09.
How many shares outstanding does Calliditas Therapeutics have?
Calliditas Therapeutics has 29,790,043 shares outstanding.
What happened to Calliditas Therapeutics’s price movement after its last earnings report?
Calliditas Therapeutics reported an EPS of -$0.856 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went up 4.79%.
Which hedge fund is a major shareholder of Calliditas Therapeutics?
Currently, no hedge funds are holding shares in CALT
---
Calliditas Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$35.17 (-9.17% Downside)
$35.17 (-9.17% Downside)
Blogger Sentiment
Bullish
CALT Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.24%
12-Months-Change
Fundamentals
Return on Equity
-145.99%
Trailing 12-Months
Asset Growth
-8.47%
Trailing 12-Months
Company Description
Calliditas Therapeutics
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
---
CALT Company Deck
---
CALT Earnings Call
Q1 2024
0:00 / 0:00
---
CALT Stock 12 Month Forecast
Average Price Target
$35.17
▼(-9.17% Downside)
Technical Analysis
Best Analysts Covering CALT
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+51.68%
reiterated a buy rating 2 months ago
Copying Jon Berggren's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +51.68% per trade.
---